Oppenheimer Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $7.73M | Buy |
17,302
+582
| +3% | +$271K | 0.09% | 259 |
|
|
2025
Q4 | $7.58M | Sell |
16,720
-8,740
| -34% | -$3.77M | 0.09% | 234 |
|
|
2025
Q3 | $9.97M | Buy |
25,460
+3,972
| +18% | +$1.66M | 0.11% | 208 |
|
|
2025
Q2 | $9.57M | Sell |
21,488
-206
| -0.9% | -$94.9K | 0.11% | 210 |
|
|
2025
Q1 | $10.5M | Buy |
21,694
+1,166
| +6% | +$543K | 0.13% | 184 |
|
|
2024
Q4 | $8.27M | Sell |
20,528
-2,862
| -12% | -$1.33M | 0.1% | 222 |
|
|
2024
Q3 | $10.9M | Sell |
23,390
-978
| -4% | -$470K | 0.13% | 180 |
|
|
2024
Q2 | $11.4M | Buy |
24,368
+9,957
| +69% | +$4.32M | 0.15% | 170 |
|
|
2024
Q1 | $6.02M | Sell |
14,411
-2,061
| -13% | -$871K | 0.09% | 251 |
|
|
2023
Q4 | $6.7M | Buy |
16,472
+2,442
| +17% | +$902K | 0.09% | 248 |
|
|
2023
Q3 | $4.88M | Sell |
14,030
-78
| -0.6% | -$27.3K | 0.07% | 286 |
|
|
2023
Q2 | $4.96M | Sell |
14,108
-200
| -1% | -$67.4K | 0.07% | 286 |
|
|
2023
Q1 | $4.51M | Sell |
14,308
-918
| -6% | -$275K | 0.07% | 296 |
|
|
2022
Q4 | $4.4M | Buy |
15,226
+116
| +0.8% | +$35.4K | 0.07% | 291 |
|
|
2022
Q3 | $4.37M | Buy |
15,110
+1,656
| +12% | +$476K | 0.08% | 275 |
|
|
2022
Q2 | $3.79M | Sell |
13,454
-796
| -6% | -$213K | 0.06% | 313 |
|
|
2022
Q1 | $3.72M | Sell |
14,250
-461
| -3% | -$109K | 0.05% | 366 |
|
|
2021
Q4 | $3.23M | Buy |
14,711
+3,268
| +29% | +$635K | 0.04% | 406 |
|
|
2021
Q3 | $2.08M | Sell |
11,443
-17,121
| -60% | -$3.34M | 0.03% | 522 |
|
|
2021
Q2 | $5.76M | Buy |
28,564
+270
| +1% | +$56.5K | 0.08% | 282 |
|
|
2021
Q1 | $6.08M | Buy |
28,294
+394
| +1% | +$86.5K | 0.09% | 249 |
|
|
2020
Q4 | $6.59M | Buy |
27,900
+1,413
| +5% | +$324K | 0.11% | 218 |
|
|
2020
Q3 | $7.21M | Buy |
26,487
+322
| +1% | +$88.8K | 0.14% | 176 |
|
|
2020
Q2 | $7.59M | Sell |
26,165
-5,165
| -16% | -$1.4M | 0.16% | 158 |
|
|
2020
Q1 | $7.45M | Sell |
31,330
-2,558
| -8% | -$587K | 0.18% | 137 |
|
|
2019
Q4 | $7.42M | Sell |
33,888
-3,185
| -9% | -$645K | 0.16% | 164 |
|
|
2019
Q3 | $6.28M | Sell |
37,073
-11,432
| -24% | -$2.02M | 0.14% | 181 |
|
|
2019
Q2 | $8.89M | Sell |
48,505
-302
| -0.6% | -$52.8K | 0.2% | 125 |
|
|
2019
Q1 | $8.98M | Sell |
48,807
-3,805
| -7% | -$703K | 0.2% | 127 |
|
|
2018
Q4 | $8.72M | Sell |
52,612
-1,581
| -3% | -$274K | 0.22% | 107 |
|
|
2018
Q3 | $10.4M | Buy |
54,193
+2,244
| +4% | +$400K | 0.23% | 106 |
|
|
2018
Q2 | $8.83M | Buy |
51,949
+15,114
| +41% | +$2.34M | 0.22% | 113 |
|
|
2018
Q1 | $6M | Buy |
36,835
+11,090
| +43% | +$1.81M | 0.15% | 168 |
|
|
2017
Q4 | $3.91M | Hold |
25,745
| – | – | 0.1% | 235 |
|
|
2017
Q3 | $3.91M | Buy |
25,745
+11,282
| +78% | +$1.7M | 0.1% | 237 |
|
|
2017
Q2 | $1.86M | Buy |
14,463
+6,836
| +90% | +$823K | 0.05% | 376 |
|
|
2017
Q1 | $834K | Buy |
+7,627
| New | +$671K | 0.02% | 632 |
|
Other funds holding VRTX
VCM
VPM
Oppenheimer Asset Management's VRTX Position: Q1 2026 in Review
Oppenheimer Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.5% in Q1 2026, buying an estimated $271K and bringing the position to 17,302 shares worth $7.73M. The position accounts for 0.09% of the portfolio, ranked #259.
Oppenheimer Asset Management first reported a position in VRTX in Q1 2017 and has held it in 37 quarters since. The position peaked at $11.4M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Oppenheimer Asset Management held 17,302 shares of Vertex Pharmaceuticals worth $7.73M as of Q1 2026.
- Oppenheimer Asset Management bought 582 Vertex Pharmaceuticals shares in Q1 2026, an estimated $271K.
- Vertex Pharmaceuticals made up 0.09% of Oppenheimer Asset Management's portfolio in Q1 2026, its #259 holding.
- Oppenheimer Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2017 and has held it in 37 quarters since.
- Oppenheimer Asset Management's Vertex Pharmaceuticals position peaked at $11.4M in Q2 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.